$TCBP
TC BioPharm (Holdings) plc

2024 Q2 Form 10-Q Financial Statement

#000149315224019840 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development 1.299M gbps
YoY Change -32.85%
% of Gross Profit
Depreciation & Amortization 114.7K gbps
YoY Change -32.17%
% of Gross Profit
Operating Expenses 3.442M gbps
YoY Change -17.38%
Operating Profit -3.442M gbps
YoY Change -17.38%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net 9.060K gbps
YoY Change -99.71%
Pretax Income -3.433M gbps
YoY Change 231.68%
Income Tax -110.7K gbps
% Of Pretax Income
Net Earnings -3.322M gbps
YoY Change 423.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$0.11
COMMON SHARES
Basic Shares Outstanding 98.90M shares 63.90M shares
Diluted Shares Outstanding 30.14M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $981.0K
YoY Change
Cash & Equivalents 1.000M gbps 2.500M gbps
Short-Term Investments
Other Short-Term Assets $2.016M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets 4.203M gbps 5.701M gbps
YoY Change -23.45%
LONG-TERM ASSETS
Property, Plant & Equipment 1.160M gbps 1.275M gbps
YoY Change -56.79%
Goodwill
YoY Change
Intangibles 608.5K gbps 615.2K gbps
YoY Change 11.24%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets 3.061M gbps 3.231M gbps
YoY Change -7.78%
TOTAL ASSETS
Total Short-Term Assets 4.203M gbps 5.701M gbps
Total Long-Term Assets 3.061M gbps 3.231M gbps
Total Assets 7.264M gbps 8.932M gbps
YoY Change -18.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable 1.928M gbps 1.847M gbps
YoY Change 109.36%
Accrued Expenses 1.013M gbps 1.229M gbps
YoY Change 30.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities 4.764M gbps 4.751M gbps
YoY Change -48.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.420M
YoY Change
Total Long-Term Liabilities $1.420M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities 4.764M gbps 4.751M gbps
Total Long-Term Liabilities $1.420M
Total Liabilities 6.184M gbps 6.246M gbps
YoY Change -43.09%
SHAREHOLDERS EQUITY
Retained Earnings -42.16M gbps -38.84M gbps
YoY Change 16.37%
Common Stock 6.391K gbps 2.057K gbps
YoY Change 2065.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity 1.080M gbps 2.685M gbps
YoY Change
Total Liabilities & Shareholders Equity 7.264M gbps 8.932M gbps
YoY Change -18.44%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -3.322M gbps
YoY Change 423.2%
Depreciation, Depletion And Amortization 114.7K gbps
YoY Change -32.17%
Cash From Operating Activities -2.400M gbps
YoY Change -17.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -5.618K gbps
YoY Change -96.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 932.6K gbps
YoY Change -76.42%
NET CHANGE
Cash From Operating Activities -2.400M gbps
Cash From Investing Activities -5.618K gbps
Cash From Financing Activities 932.6K gbps
Net Change In Cash -1.482M gbps
YoY Change -265.04%
FREE CASH FLOW
Cash From Operating Activities -2.400M gbps
Capital Expenditures
Free Cash Flow -2.400M gbps
YoY Change -20.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41231
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
TC BIOPHARM (HOLDINGS) PLC
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Maxim 1, 2 Parklands Way
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Holytown
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Motherwell
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
ML1 4WR
CY2024Q1 dei Entity Address Country
EntityAddressCountry
GB
CY2024Q1 dei City Area Code
CityAreaCode
+44 (0)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
141 433 7557
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001872812
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
gbp
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
gbp
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
gbp
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
gbp
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
gbp
CY2024Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
gbp
CY2024Q1 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
gbp
CY2024Q1 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
gbp
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98902641 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
980955 gbp
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2462609 gbp
CY2024Q1 TCBP Corporation Tax Receivable
CorporationTaxReceivable
1154335 gbp
CY2023Q4 TCBP Corporation Tax Receivable
CorporationTaxReceivable
1043593 gbp
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2067490 gbp
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2194725 gbp
CY2024Q1 us-gaap Assets Current
AssetsCurrent
4202780 gbp
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5700927 gbp
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1160053 gbp
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1274798 gbp
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1292708 gbp
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1340769 gbp
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
608512 gbp
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
615170 gbp
CY2024Q1 us-gaap Assets
Assets
7264053 gbp
CY2023Q4 us-gaap Assets
Assets
8931664 gbp
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4453447 gbp
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4431840 gbp
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1991 gbp
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
13437 gbp
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
308158 gbp
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
305324 gbp
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4763596 gbp
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4750601 gbp
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1419969 gbp
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1495833 gbp
CY2024Q1 us-gaap Liabilities
Liabilities
6183565 gbp
CY2023Q4 us-gaap Liabilities
Liabilities
6246434 gbp
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
63902641 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63902641 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63902641 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20570088 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20570088 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20570088 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
6391 gbp
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2057 gbp
CY2024Q1 TCBP Deferred Stock Par Or Stated Value Per Share
DeferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 TCBP Deferred Stock Par Or Stated Value Per Share
DeferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 TCBP Deferred Stock Shares Authorized
DeferredStockSharesAuthorized
794955 shares
CY2024Q1 TCBP Deferred Stock Shares Issued
DeferredStockSharesIssued
794955 shares
CY2024Q1 TCBP Deferred Stock Shares Outstanding
DeferredStockSharesOutstanding
794955 shares
CY2023Q4 TCBP Deferred Stock Shares Authorized
DeferredStockSharesAuthorized
794955 shares
CY2023Q4 TCBP Deferred Stock Shares Issued
DeferredStockSharesIssued
794955 shares
CY2023Q4 TCBP Deferred Stock Shares Outstanding
DeferredStockSharesOutstanding
794955 shares
CY2024Q1 TCBP Deferred Stock Value
DeferredStockValue
397398 gbp
CY2023Q4 TCBP Deferred Stock Value
DeferredStockValue
397398 gbp
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42835843 gbp
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41123065 gbp
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42159144 gbp
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38837290 gbp
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1080488 gbp
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2685230 gbp
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7264053 gbp
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8931664 gbp
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1298942 gbp
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1934304 gbp
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2142714 gbp
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2231461 gbp
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3441656 gbp
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4165765 gbp
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3441656 gbp
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4165765 gbp
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11446 gbp
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3148648 gbp
CY2024Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2386 gbp
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
17794 gbp
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9060 gbp
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3130854 gbp
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3432596 gbp
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1034911 gbp
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-110742 gbp
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000 gbp
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3321854 gbp
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-634911 gbp
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30138602 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30138602 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2051836 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2051836 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
331265 gbp
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
139815 gbp
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1280449 gbp
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-634911 gbp
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1116618 gbp
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2685230 gbp
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2685230 gbp
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
784797 gbp
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
912792 gbp
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19523 gbp
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3321854 gbp
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1080488 gbp
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1080488 gbp
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3321854 gbp
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-634911 gbp
CY2024Q1 us-gaap Depreciation
Depreciation
114745 gbp
CY2023Q1 us-gaap Depreciation
Depreciation
169155 gbp
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12276 gbp
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11815 gbp
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
784555 gbp
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
139815 gbp
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11446 gbp
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3148648 gbp
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
219830 gbp
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
17214 gbp
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
11705 gbp
CY2024Q1 TCBP Increase Decrease In In Corporation Tax Receivable
IncreaseDecreaseInInCorporationTaxReceivable
110742 gbp
CY2023Q1 TCBP Increase Decrease In In Corporation Tax Receivable
IncreaseDecreaseInInCorporationTaxReceivable
400000 gbp
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-127236 gbp
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-332510 gbp
CY2024Q1 TCBP Increase Decrease In Operating Lease Liability Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilityRightOfUseAsset
-48061 gbp
CY2023Q1 TCBP Increase Decrease In Operating Lease Liability Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilityRightOfUseAsset
-46211 gbp
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
21607 gbp
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
447418 gbp
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-73031 gbp
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88933 gbp
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2408593 gbp
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2911247 gbp
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120182 gbp
CY2024Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5618 gbp
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25051 gbp
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5618 gbp
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145233 gbp
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
986772 gbp
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2673789 gbp
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19765 gbp
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1439414 gbp
CY2024Q1 TCBP Payments Of Stock And Warrant Issuance Costs
PaymentsOfStockAndWarrantIssuanceCosts
73980 gbp
CY2023Q1 TCBP Payments Of Stock And Warrant Issuance Costs
PaymentsOfStockAndWarrantIssuanceCosts
158965 gbp
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
932557 gbp
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3954238 gbp
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1481654 gbp
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
897758 gbp
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2462609 gbp
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4808060 gbp
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
980955 gbp
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5705818 gbp
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
65750 shares
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0001
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0001
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
140000 shares
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
100
CY2023Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
35
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
623750 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1000000.0 gbp
CY2024Q1 TCBP Working Capital Deficit
WorkingCapitalDeficit
600000 gbp
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2400000 gbp
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3300000 gbp
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_zMRtl0IYZVv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z3LDeWKeU8J6">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.20 pure
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1000000.0 gbp
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2500000 gbp
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zRNbPkJ7a463" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zW0ySmoZ5Wzj">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains substantially all of its cash and cash equivalents with financial institutions, which, at times, may exceed federally insured limits. The Company has not incurred any losses associated with this concentration of deposits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently has bank deposits with financial institutions in the U.S. of approximately £<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_uGBP_c20240331_zUVa7803PyV3" title="FDCI Insured amount">0.2</span> million as of March 31, 2024 which are below the FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_uUSD_c20240331_zlVy3x43zYF7" title="FDIC insured amount">250,000</span>. The Company had approximately £<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_pn5n6_uGBP_c20240331_zG9oXCIA9JH2" title="Uninsured bank deposits">0.8</span> million in uninsured bank deposits with financial institutions outside the U.S as of March 31, 2024. All uninsured bank deposits are held at high quality credit institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
200000 gbp
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
800000 gbp
CY2023Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P16Y
CY2024Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 gbp
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 gbp
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3321854 gbp
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-634911 gbp
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30138602 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30138602 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2051836 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2051836 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5432180 gbp
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5432180 gbp
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4157382 gbp
CY2024Q1 us-gaap Depreciation
Depreciation
114745 gbp
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4272127 gbp
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1160053 gbp
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1274798 gbp
CY2024Q1 us-gaap Depreciation
Depreciation
114745 gbp
CY2023Q1 us-gaap Depreciation
Depreciation
169155 gbp
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
860606 gbp
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
860606 gbp
CY2024Q1 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
5618 gbp
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
866224 gbp
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
866224 gbp
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
245436 gbp
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12276 gbp
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
257712 gbp
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
608512 gbp
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
615170 gbp
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12276 gbp
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11815 gbp
CY2024Q1 us-gaap Other Receivables
OtherReceivables
51826 gbp
CY2023Q4 us-gaap Other Receivables
OtherReceivables
51584 gbp
CY2024Q1 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
66957 gbp
CY2023Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
135642 gbp
CY2024Q1 TCBP Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
307519 gbp
CY2023Q4 TCBP Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
307519 gbp
CY2024Q1 TCBP Deferred Clinical Trial Testing Costs
DeferredClinicalTrialTestingCosts
1177500 gbp
CY2023Q4 TCBP Deferred Clinical Trial Testing Costs
DeferredClinicalTrialTestingCosts
1177500 gbp
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
463688 gbp
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
522480 gbp
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2067490 gbp
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2194725 gbp
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1927612 gbp
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1847279 gbp
CY2024Q1 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
290255 gbp
CY2023Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
139029 gbp
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1013162 gbp
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1229419 gbp
CY2024Q1 TCBP Accrued In Respect To Clinical Trial Testing
AccruedInRespectToClinicalTrialTesting
1177500 gbp
CY2023Q4 TCBP Accrued In Respect To Clinical Trial Testing
AccruedInRespectToClinicalTrialTesting
1177500 gbp
CY2024Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
44918 gbp
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
38613 gbp
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4453447 gbp
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4431840 gbp
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
86785 gbp
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
86291 gbp
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
111754 gbp
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
111754 gbp
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M28D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M9D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.086 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.086 pure
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
335261 gbp
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
447015 gbp
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
447015 gbp
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
447015 gbp
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
447015 gbp
CY2024Q1 TCBP Lessee Operating Lease Liability Undiscounted Excess Amount And Imputed Interest
LesseeOperatingLeaseLiabilityUndiscountedExcessAmountAndImputedInterest
395194 gbp
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1728127 gbp
CY2021Q2 us-gaap Convertible Debt
ConvertibleDebt
20000000 usd
CY2021Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05 pure
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
809692 usd
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
14228245 usd
CY2023 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
CY2022 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
3195765 usd
CY2023 us-gaap Long Term Debt Average Amount Outstanding
LongTermDebtAverageAmountOutstanding
0 gbp
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
140000 shares
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
100
CY2023Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
35
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
623750 shares
CY2023Q4 TCBP Stockholders Equity American Depositary Shares Description
StockholdersEquityAmericanDepositarySharesDescription
On December 15, 2023, the Company changed its ratio of ADSs ordinary shares from one ADS representing one ordinary share to one ADS representing 20 ordinary shares.
CY2024Q1 TCBP Weighted Average Fair Value Of Options
WeightedAverageFairValueOfOptions
0.93
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
248659 gbp
CY2020Q3 TCBP Share Based Compensation Arrangement By Additional Right To Subscribe For Shares
ShareBasedCompensationArrangementByAdditionalRightToSubscribeForShares
15891 shares
CY2020Q3 us-gaap Share Price
SharePrice
215.00
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1000000.0 gbp
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.5814
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-019840-index-headers.html Edgar Link pending
0001493152-24-019840-index.html Edgar Link pending
0001493152-24-019840.txt Edgar Link pending
0001493152-24-019840-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcbp-20240331.xsd Edgar Link pending
tcbp-20240331_lab.xml Edgar Link unprocessable
tcbp-20240331_pre.xml Edgar Link unprocessable
tcbp-20240331_cal.xml Edgar Link unprocessable
tcbp-20240331_def.xml Edgar Link unprocessable